Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 17/20 | 0.73 |
| ▸ | PLK3 | Q9H4B4 | 2/20 | 0.73 |
| ▸ | CDK2 | P24941 | 1/20 | 0.73 |
| ▸ | NEK5 | Q6P3R8 | 1/20 | 0.68 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.51 |
| ▸ | JAK2 | O60674 | 1/20 | 0.51 |
| ▸ | INSR | P06213 | 1/20 | 0.51 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3994664 | 0.85 | PLK1 (1.00) | PLK1PLK3CDK2NEK5PTK2 | |
| SCHEMBL3994224 | 0.84 | PLK1 (1.00) | PLK1PLK3CDK2NEK5PTK2 | |
| SCHEMBL3994202 | 0.81 | PLK1 (0.83) | PLK1PLK3CDK2NEK5PTK2 | |
| SCHEMBL3994431 | 0.81 | PLK1 (1.00) | PLK1PLK3CDK2NEK5PTK2 | |
| SCHEMBL3995502 | 0.81 | NEK5 (1.00) | PLK1PLK3CDK2NEK5PTK2 | |
| SCHEMBL3994128 | 0.79 | PLK1 (0.71) | PLK1PLK3CDK2NEK5PTK2 | |
| SCHEMBL3995532 | 0.79 | PLK1 (1.00) | PLK1PLK3CDK2NEK5PTK2 | |
| SCHEMBL3992071 | 0.78 | PLK1 (1.00) | PLK1PLK3CDK2NEK5PTK2 | |
| SCHEMBL3994175 | 0.78 | PLK1 (0.80) | PLK1PLK3CDK2NEK5PTK2 | |
| SCHEMBL3992107 | 0.78 | PLK1 (0.74) | PLK1PLK3CDK2NEK5PTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1608656-B1 | IMIDAZOTRIAZINE COMPOUNDS FOR THE TREATMENT OF CANCER DISEASES | SMITHKLINE BEECHAM CORP (US) | 2009-06-03 | — | — | EP | claimed |